We are live on ! Find out more
ZYNE

Zynerba Pharmaceuticals, Inc
ZYNE

Delisted

ZYNE was delisted on the 10th of October, 2023.

Back to rankings

0 hedge funds and large institutions have $0 invested in Zynerba Pharmaceuticals, Inc in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 43 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 43 → 0 (-43)

100% less capital invested

Capital invested by funds: $14.7M → $0 (-$14.7M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 43

Holders
–
Holders Change
-43
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
43
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BCM
Beryl Capital Management
California
-$6.25M
2
HCM
Highbridge Capital Management
New York
-$2.91M
3
YCM
Yakira Capital Management
Connecticut
-$791K
4
Renaissance Technologies
Renaissance Technologies
New York
-$772K
5
CL
CSS LLC
Illinois
-$608K
Name Holding Trade Value Shares
Change 		Change in
Stake
BCM
1
Beryl Capital Management
California
– -$6.25M -4,898,927 Closed
HCM
2
Highbridge Capital Management
New York
– -$2.91M -2,283,979 Closed
YCM
3
Yakira Capital Management
Connecticut
– -$791K -620,019 Closed
Renaissance Technologies
4
Renaissance Technologies
New York
– -$772K -605,700 Closed
CL
5
CSS LLC
Illinois
– -$608K -476,831 Closed
DAM
6
Deltec Asset Management
New York
– -$606K -475,000 Closed
Millennium Management
7
Millennium Management
New York
– -$413K -325,237 Closed
Jane Street
8
Jane Street
New York
– -$360K -282,478 Closed
CM
9
Crystalline Management
Canada
– -$294K -230,817 Closed
Susquehanna International Group
10
Susquehanna International Group
Pennsylvania
– -$282K -221,719 Closed
PCM
11
Penserra Capital Management
California
– -$280K -220,858 Closed
HF
12
HRT Financial
New York
– -$258K -203,229 Closed
PCM
13
PenderFund Capital Management
British Columbia, Canada
– -$213K -123,444 Closed
GS
14
GTS Securities
New York
– -$153K -120,121 Closed
FLC
15
Fifth Lane Capital
Texas
– -$127K -100,000 Closed
Northern Trust
16
Northern Trust
Illinois
– -$58.7K -46,072 Closed
Geode Capital Management
17
Geode Capital Management
Massachusetts
– -$48.2K -37,934 Closed
Charles Schwab
18
Charles Schwab
California
– -$47.7K -37,596 Closed
Morgan Stanley
19
Morgan Stanley
New York
– -$44.3K -34,783 Closed
CAN
20
Cetera Advisor Networks
California
– -$28.2K -22,124 Closed
JP Morgan Chase
21
JP Morgan Chase
New York
– -$26.5K -20,875 Closed
UBS Group
22
UBS Group
Switzerland
– -$26K -20,385 Closed
XT
23
XTX Topco
Cayman Islands
– -$23.9K -18,793 Closed
Osaic Holdings
24
Osaic Holdings
Arizona
– -$20.6K -16,161 Closed
KWMG
25
King Wealth Management Group
Florida
– -$20K -16,000 Closed
1
2

ZYNE Hedge Fund Activity: Q4 2023 in Review

0 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Zynerba Pharmaceuticals, Inc (ZYNE) for Q4 2023, worth a combined $0 — down 100% from $14.7M a quarter earlier.

Sellers outnumbered buyers: 43 funds closed out of ZYNE and 0 opened new positions — a net loss of 43 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Beryl Capital Management, exiting entirely with an estimated $6.25M sold.

  • 0 institutional investors held Zynerba Pharmaceuticals, Inc (ZYNE) as of Q4 2023, down from 43 in Q3 2023.
  • Funds reported $0 of Zynerba Pharmaceuticals, Inc stock for Q4 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Zynerba Pharmaceuticals, Inc positions in Q4 2023 and 43 closed out, a net change of -43 holders.
  • The largest Zynerba Pharmaceuticals, Inc seller in Q4 2023 was Beryl Capital Management, an estimated $6.25M sold.

Based on aggregated 13F filings for Q4 2023.